A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC) Meeting Abstract


Authors: Spigel, D. R.; Reckamp, K. L.; Rizvi, N. A.; Poddubskaya, E.; West, H. J.; Eberhardt, W. E. E.; Baas, P.; Antonia, S. J.; Pluzanski, A.; Vokes, E. E.; Holgado, E.; Waterhouse, D. M.; Ready, N.; Gainor, J. F.; Aren, O. R.; Horn, L.; Paz-Ares, L.; Baudelet, C.; Lestini, B. J.; Brahmer, J. R.
Abstract Title: A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC)
Meeting Title: 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 33
Issue: 15 Suppl.
Meeting Dates: 2015 May 29-Jun 2
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2015-05-20
Language: English
ACCESSION: WOS:000358036901722
PROVIDER: wos
Notes: Meeting Abstract: 8009 -- Source: Wos